Medication info
Irbesartan Plus Tablet 150/12.5 mg

Irbesartan Plus Tablet 150/12.5 mg

Prescription medicationTabletOral
Ingredient · strength
Irbesartan›150mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Korea Pharma Co., Ltd.
Appearance
Pink, double convex, oblong film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201205244 · Approved 2012.05.30 · Insurance code 653005050

Summary

Main use
Treatment of essential hypertension
Who takes it
Adults · Children
Adult dose
This medicine is administered once daily, with or without food. Titration of each component (irbesartan and hydrochlorothiazide) is recommended. ○ Adults 1. Patients whose blood pressure is not adequately controlled with monotherapy - In patients whose blood pressure is not adequately controlled with irbesartan 150 mg or hydrochlorothiazide alone, administer 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily. - In patients whose blood pressure is not adequately controlled with irbesartan 300 mg or irbesartan 150 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 12.5 mg once daily. - In patients whose blood pressure is not adequately controlled with irbesartan 300 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 25 mg once daily. Doses exceeding irbesartan 300 mg/hydrochlorothiazide 25 mg are not recommended. If necessary, this medicine may be administered concomitantly with other antihypertensive agents. 2. When initiating treatment in patients with moderate or severe hypertension (stage 2), the regimen should be individualized, taking into account baseline blood pressure, the target blood pressure, and the expected increase in the likelihood of achieving the treatment goal compared with monotherapy. Treatment is usually started with 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily; if blood pressure control is needed, the dose may be increased after 1 ~ 2 weeks to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg. Initiating treatment with this medicine is not recommended in patients with intravascular volume depletion. ○ Patients with renal impairment Because of the hydrochlorothiazide component, this medicine is not recommended for patients with severe renal impairment (creatinine clearance〈 30 mL/min). Loop diuretics are preferred in this patient population. No dose adjustment is necessary in patients with renal impairment and creatinine clearance of 30 mL/min or greater. ○ Patients with volume depletion If sodium and/or fluid depletion is present, it should be corrected before administering this medicine. ○ Patients with hepatic impairment This medicine should not be used in patients with severe hepatic impairment. Thiazide drugs should be used with caution in patients with hepatic impairment. No dose adjustment is necessary in patients with mild ~ moderate hepatic impairment. ○ Older adults No dose adjustment is necessary in older adults.
Child dose
○ Pediatric patients The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Korea Pharma Co., Ltd.

Efficacy & effects

Treatment of essential hypertension

  • Essential hypertension
  • moderate hypertension
  • severe hypertension
View approved original text

This medication is used for patients with essential hypertension and is utilized as a first-line therapy requiring combination treatment to achieve target blood pressure in cases where blood pressure control is difficult with monotherapy or in moderate to severe hypertension patients. Therefore, it is used to effectively assist in blood pressure management and stabilize blood pressure.

How to take

Adult dose

This medicine is administered once daily, with or without food. Titration of each component (irbesartan and hydrochlorothiazide) is recommended. ○ Adults 1. Patients whose blood pressure is not adequately controlled with monotherapy - In patients whose blood pressure is not adequately controlled with irbesartan 150 mg or hydrochlorothiazide alone, administer 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily. - In patients whose blood pressure is not adequately controlled with irbesartan 300 mg or irbesartan 150 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 12.5 mg once daily. - In patients whose blood pressure is not adequately controlled with irbesartan 300 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 25 mg once daily. Doses exceeding irbesartan 300 mg/hydrochlorothiazide 25 mg are not recommended. If necessary, this medicine may be administered concomitantly with other antihypertensive agents. 2. When initiating treatment in patients with moderate or severe hypertension (stage 2), the regimen should be individualized, taking into account baseline blood pressure, the target blood pressure, and the expected increase in the likelihood of achieving the treatment goal compared with monotherapy. Treatment is usually started with 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily; if blood pressure control is needed, the dose may be increased after 1 ~ 2 weeks to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg. Initiating treatment with this medicine is not recommended in patients with intravascular volume depletion. ○ Patients with renal impairment Because of the hydrochlorothiazide component, this medicine is not recommended for patients with severe renal impairment (creatinine clearance〈 30 mL/min). Loop diuretics are preferred in this patient population. No dose adjustment is necessary in patients with renal impairment and creatinine clearance of 30 mL/min or greater. ○ Patients with volume depletion If sodium and/or fluid depletion is present, it should be corrected before administering this medicine. ○ Patients with hepatic impairment This medicine should not be used in patients with severe hepatic impairment. Thiazide drugs should be used with caution in patients with hepatic impairment. No dose adjustment is necessary in patients with mild ~ moderate hepatic impairment. ○ Older adults No dose adjustment is necessary in older adults.

Child dose

○ Pediatric patients The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during pregnancy; therefore, it must be discontinued immediately upon confirmation of pregnancy. This medication should not be taken by pregnant women, women of childbearing potential, or nursing mothers. It should also be avoided in patients with allergy to this medication or its components or certain kidney dysfunction. It is unsuitable for patients with severely impaired kidney function or anuria. Caution is required for patients with severe liver dysfunction or certain liver diseases. Patients with a history of angioedema or experiencing angioedema due to similar medications should not take this medication. Patients with hereditary lactose intolerance should also refrain from this medication. Patients with specific health conditions such as hypotension, renal artery stenosis, renal transplant recipients, or liver impairment should take this medication with special caution. Due to the hydrochlorothiazide component, there is an increased risk of skin cancer, so it is necessary to minimize sun exposure and regularly check skin conditions. Side effects such as dizziness, fatigue, nausea, vomiting, and abnormal urination may occur upon taking this medication, and renal function indicators may change in blood tests. Serum potassium levels may particularly change, requiring regular blood tests. Caution is needed when driving or operating machinery due to dizziness or fatigue. This medication can be used in combination with other antihypertensive medications but should be avoided with lithium preparations as it can increase toxicity. Patients being treated for diabetes may have a risk of hypoglycemia, so they should consult a doctor before taking this medication, and dosage adjustments for blood sugar control medications may be needed. This medication should not be taken during pregnancy or nursing, and safety for children and adolescents has not been established, so it is not recommended for them. Older adults may also respond sensitively to this medication, so caution is advised. In the case of overdose, signs such as hypotension, electrolyte imbalances, and dehydration may occur, and immediate medical treatment should be sought. This medication should be stored out of reach of children and kept in the original container to maintain its quality.

Side effects

Dizziness, fatigue, nausea, vomiting, abnormal urination, elevated BUN, elevated creatine kinase, elevated creatinine, orthostatic dizziness, headache, fainting, low blood pressure, tachycardia, edema, flushing, cough, diarrhea, dyspepsia, taste disorder, jaundice, hepatitis, abnormal liver function, sexual dysfunction, changes in libido, kidney function impairment, limb edema, arthralgia, myalgia, tinnitus, angioedema, rash, urticaria, hyperkalemia, decreased serum potassium, decreased serum sodium, low blood pressure, shingles, colon cancer, hematoma, anaphylactic shock, anaphylactic reaction, intestinal vascular edema, anemia, thrombocytopenia, hypoglycemia, depression, sleep disturbances, orthostatic hypotension, arrhythmia, aplastic anemia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, leukopenia, thrombocytopenia, shortness of breath, pancreatitis, loss of appetite, constipation, gastric irritation, sialadenitis, loss of appetite, interstitial nephritis, kidney dysfunction, jaundice, temporary blurred vision, xanthopsia, weakness, muscle cramps, anaphylactoid reaction, toxic epidermal necrolysis, necrotizing vasculitis, cutaneous erythematous lupus-like reaction, cutaneous erythematous lupus reactivation, photosensitivity reaction, rash, urticaria, fever, electrolyte imbalance, hyperuricemia, diabetes, hyperglycemia, elevated cholesterol and triglycerides, hypoglycemia, hypokalemia, hypochloremia, hyponatremia, muscle spasms, drowsiness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it must be stored in a tightly closed container. It is important to maintain a storage temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Pink, double convex, oblong film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.